Chemours Co (CC) Form 10-Q — Aug 5, 2026
Chemours reported Q2 2026 net sales of $1,591 million, down about 1.5% year over year, with a net loss attributable to Chemours of $274 million, or $(1.81) per share, versus a $380 million loss, or $(2.53), a year earlier. The narrowed loss was driven by $273 million of other income, largely a $266 million gain on asset and business sales, while core operations remained loss-making with SG&A of $469 million exceeding gross profit of $286 million. The balance sheet deteriorated: total stockholders' equity turned negative at $(48) million at June 30, 2026 from positive $251 million at year-end 2025, and total debt stands at roughly $3,872 million.
Key figures
- Revenue
- 1591
- Revenue Yoy
- -1.5%
- Total Assets
- 7150
- Cash Position
- 671
- Shares Outstanding
- 150498995
- Q2 2026 sga
- 469
- Asbestos accrual
- 93
- H1 2026 net sales
- 2972
- Q2 2026 gross profit
- 286
- Revolver commitments
- 780 maturing May 2, 2030 and 220 maturing October 7, 2026
- Pfas cost share mou cap
- 4000
- Afff mdl matters pending
- ~13,400 (approx. 900 water provider cases, ~12,500 other)
- Q2 2026 other income net
- 273
- Accrued litigation dec 2025
- 484
- Accrued litigation jun 2026
- 658
- H1 2026 asset sale proceeds
- 294
- H1 2026 gain on asset sales
- 266
- H1 2026 operating cash flow
- 114
- Other pfas accrual dec 2025
- 344
- Other pfas accrual jun 2026
- 552
- Cash at foreign subsidiaries
- 516
- Q2 2026 net sales prior year
- 1615
- Pfas cost share mou available
- ~1,300
- Revolving credit availability
- 953
- H1 2026 debt issuance proceeds
- 700
- Dividends declared h1 2025 per share
- 0.3375
- Dividends declared h1 2026 per share
- 0.175
Price after filing
Close on the filing date to close N calendar days later (from $17.11). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.